Hepatocellular Carcinoma (HCC) is one of the major frequent cause of cancer-related mortality worldwide. Combination of different chemotherapeutics drugs may offer advantages for the treatment of HCC. Targeted hepatocellular carcinoma therapy was carried out to improve the efficacy of liver cancer treatment. The purpose of this study was to design an N-acetylgalactosamine (NAcGal) modified and pH sensitive doxorubicin (DOX) prodrug (NAcGal-DOX) for the construction of lipid nanoparticles (LNPs) .Nanotechnology has made exceptional headway, emerging as a revolutionary platform to treat a wide variety of tumors, mainly due to prolonged drug release, as well as increased cell internalization. In this work, we have developed a drug delivery system, a hybrid nanoparticle formulation, which allows the specific delivery into HCC cells.
Published Date: 2020-12-15; Received Date: 2020-11-23